Cala Receives FDA Clearance for Next-Generation kIQ Plus Wearable Device for Essential Tremor and Parkinson's Disease

Key Takeaways

• FDA clears Cala’s next-generation kIQ Plus wearable device for treating hand tremors in essential tremor and Parkinson’s disease patients
• Advanced TAPS technology features new therapy modes and adaptive calibration for optimized tremor relief and personalized treatment
• Represents significant advancement in non-invasive bioelectronic medicine for neurological movement disorders

---

FDA Approves Advanced Tremor Treatment Technology

Cala, a leading bioelectronic medicine company, announced on April 15, 2026, that the U.S. Food and Drug Administration has granted clearance for its Cala kIQ Plus system, an advanced wearable neurostimulation device designed to treat action hand tremor in patients with essential tremor (ET) and Parkinson’s disease (PD).

Enhanced TAPS Technology for Better Patient Outcomes

The kIQ Plus system represents the latest evolution of Cala’s proprietary Targeted Afferent Peripheral Stimulation (TAPS) technology. This next-generation device introduces innovative therapy modes and adaptive calibration capabilities specifically engineered to optimize tremor relief while providing personalized treatment experiences for individual patients.

Market Impact and Clinical Significance

This FDA clearance positions Cala to expand its footprint in the growing digital therapeutics market, particularly within neurology applications. Essential tremor affects approximately 10 million Americans, while Parkinson’s disease impacts over 1 million individuals in the United States. The availability of a non-invasive, wearable treatment option addresses a significant unmet medical need for patients seeking alternatives to traditional pharmaceutical interventions or surgical procedures.

Technology Advancement in Bioelectronic Medicine

The kIQ Plus system’s adaptive calibration feature represents a notable advancement in personalized medicine, allowing the device to adjust stimulation parameters based on individual patient responses and tremor patterns. This technology could potentially improve treatment adherence and clinical outcomes compared to one-size-fits-all therapeutic approaches.

Commercial and Regulatory Implications

With FDA clearance secured, Cala can now proceed with commercial distribution of the kIQ Plus system to healthcare providers and patients across the United States. This regulatory milestone validates the company’s bioelectronic medicine platform and may accelerate adoption among neurologists and movement disorder specialists treating tremor patients.

---

Frequently Asked Questions

What conditions does the Cala kIQ Plus treat?

The device is FDA-cleared for treating action hand tremor in patients with essential tremor (ET) and Parkinson’s disease (PD).

When will the kIQ Plus be available to patients?

With FDA clearance announced April 15, 2026, Cala can now begin commercial distribution, though specific availability timelines have not been disclosed.

How does TAPS technology work compared to other tremor treatments?

TAPS uses targeted peripheral nerve stimulation through a wearable device, offering a non-invasive alternative to medications or surgical interventions like deep brain stimulation.